[Systemic Rosai-Dorfman-Destombes disease associated with a myelodysplastic syndrome. Efficacy of hematologic treatment]

Rev Med Interne. 2021 Apr;42(4):281-284. doi: 10.1016/j.revmed.2021.01.001. Epub 2021 Jan 21.
[Article in French]

Abstract

Introduction: We report an original observation of multifocal refractory Destombes-Rosai-Dorfman disease associated with a myelodysplastic syndrome. The treatment of myelodysplasia allowed a good and prolonged response of both pathologies.

Case report: A 35-year-old patient was investigated for bilateral exophthalmia, histologically related to Destombes-Rosai-Dorfman disease. The extension workup showed sinus, kidney and lymph node involvement. It was treated unsuccessfully with corticosteroids, colchicine, methotrexate, infliximab, cladribine and tociluzimab. The secondary appearance of myelodysplasia (AREB IPSS score intermediate-2) led to induction treatment with aracytin and idarubicin, and maintenance with azacytidine for 2 years. With 5 years of follow-up, the patient is in remission both of the myelodysplastic syndrome and Destombes-Rosai-Dorfman disease.

Conclusion: Our observation discusses the interest of the treatment of myelodysplastic syndrome for the management of associated extra-hematological manifestations.

Keywords: Azacytidine; Destombes-Rosai-Dorfman; Histiocytose; Myélodysplasie; azacytidine; histiocytosis; myelodysplastic syndrome.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones
  • Adult
  • Histiocytosis, Sinus* / complications
  • Histiocytosis, Sinus* / diagnosis
  • Histiocytosis, Sinus* / therapy
  • Humans
  • Myelodysplastic Syndromes* / complications
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / therapy

Substances

  • Adrenal Cortex Hormones